

A novel ARMS-based assay for the quantification of *EGFR* mutations in patients with lung adenocarcinoma

YAZHEN ZHU^{1*}, ZHIWEI GUO^{2*}, YING LIU¹, XIYUN ZHENG¹, GUOHUA YANG² and GUANGJUAN ZHENG¹

¹Department of Pathology, Guangdong Provincial Hospital of TCM, Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510120;

²GenoSaber Biotech Co., Ltd., Shanghai 201203, P.R. China

Received July 26, 2017; Accepted November 21, 2017

DOI: 10.3892/ol.2017.7679

Abstract. Quantification of epidermal growth factor receptor (*EGFR*) mutations is important for the prediction of tyrosine kinase inhibitor (TKI) efficacy in patients with non-small cell lung cancer (NSCLC). However, clinicians lack a sensitive and convenient method to quantify *EGFR* mutant abundance. The present study introduces a novel method, namely amplification refractory mutation system (ARMS)-Plus, for the quantitative analysis of *EGFR* exon 19 deletion (*19Del*), *L858R* and *T790M* mutations. Formalin-fixed paraffin-embedded tumor samples were collected from 77 patients with lung adenocarcinoma. DNA was extracted and analyzed for *EGFR* mutations using ARMS-Plus. The performance of ARMS-Plus was then compared with that of conventional ARMS-polymerase chain reaction (ARMS-PCR) and droplet digital PCR (ddPCR). The results demonstrated that the concordance rate of *EGFR*

mutation testing between ARMS-Plus and ddPCR was 98.7% (76/77, Kappa=0.9739). *19Del* and *L858R* mutations were detected in 23 and 12 patients, respectively. There was a significant difference between ARMS-Plus and ddPCR in the evaluation of *19Del* mutant abundance ($P=0.0002$); however, not in that of *L858R* mutant abundance ($P=0.7334$). The ARMS-Plus results in *L858R* mutant abundance were concordant with that of ddPCR ($R^2=0.8081$). These results indicated that the sensitivity and specificity of ARMS-Plus in identifying *EGFR* mutations were similar to that of ddPCR. For quantitative analysis, the results of ARMS-Plus in evaluating *L858R* mutant abundance revealed a positive correlation with the ddPCR results. Thus, ARMS-Plus provides an alternative method, which is reliable and cost-effective, to quantify *EGFR* mutations and thereby, aid treatment decisions in patients with lung adenocarcinoma.

Correspondence to: Dr Guohua Yang, GenoSaber Biotech Co., Ltd., Block 26, Lane 908 Ziping Road, Pudong, Shanghai 201203, P.R. China

E-mail: ghyang@genosaber.cn

Dr Guangjuan Zheng, Department of Pathology, Guangdong Provincial Hospital of TCM, Guangzhou University of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, 111 Dade Road, Guangzhou, Guangdong 510120, P.R. China
E-mail: zhengguangjuan@163.com

Abbreviations: ARMS, amplification refractory mutation system; CFDA, China Food and Drug Administration; PCR, polymerase chain reaction; ddPCR, droplet digital PCR; *EGFR*, epidermal growth factor receptor; *19Del*, exon 19 deletion; FFPE, formalin-fixed paraffin-embedded; MAPK, mitogen-activated protein kinase; NSCLC, non-small cell lung cancer; PFS, progression-free survival; SNP, single nucleotide polymorphism; TKIs, tyrosine kinase inhibitors

*Contributed equally

Key words: epidermal growth factor receptor, non-small cell lung cancer, amplification refractory mutation system, droplet digital polymerase chain reaction, formalin-fixed paraffin-embedded

Introduction

Lung cancer, being the leading cause of cancer-related mortality, results in over 1 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. The prognosis of NSCLC is poor, with a 5-year overall survival rate of less than 20% (1). Epidermal growth factor receptor (*EGFR*) is a transmembrane receptor tyrosine kinase frequently over-expressed in NSCLC (2). Activation of *EGFR* induces the proliferation and growth of cancer cells and thus *EGFR* is a promising target for personalized therapy. Recently, *EGFR*-tyrosine kinase inhibitor (TKI) such as Gefitinib (AstraZeneca, London, UK), Erlotinib (Genentech, San Francisco, USA) and Afatinib (Boehringer Ingelheim, Ingelheim, Germany) have emerged as the first-line therapy for the treatment of NSCLC (3-5). Through selectively binding at the ATP-binding site of the receptor kinase domain, TKIs block *EGFR* activation and its downstream signal transduction, such as STAT3, MAP kinase (MAPK) and AKT signaling (6). Although the *EGFR*-TKIs show a rapid and dramatic tumor regression in NSCLC patients, the initial clinical study with Gefitinib in 2005 illustrated that only 9-19% of unselected patients with advanced NSCLC showed responses to the treatment (7,8). Subsequently, researchers reported that *EGFR* mutation status may be a key predictive factor in determining the

efficacy of EGFR-TKIs treatment (9). Exon 19 deletions (*19Del*) and *L858R* substitution mutations were found to be the most common *EGFR* mutations, which constitute about 90% of all *EGFR* mutations (10). Several studies revealed that NSCLC patients with *EGFR* mutations showed better prognosis on EGFR-TKIs therapy. This was validated by two phase II clinical trials, which demonstrated an overall response rate of 75-78% for Gefitinib in NSCLC patients harboring *EGFR* mutations (11,12). Nevertheless, secondary mutations frequently arise after first-generation EGFR-TKIs treatment and lead to therapeutic resistance. *T790M* mutation is the major cause of resistance to first-generation EGFR-TKIs, accounting for about 70% of acquired resistance (13). *T790M* mutation was reported to associate with a shorter progression-free survival (PFS) with EGFR-TKIs therapy in NSCLC patients (14). The relative *EGFR* mutant abundance may also be a key factor in predicting the sensitivity of EGFR-TKIs. Zhou *et al* reported that advanced NSCLC patients with a high abundance of *EGFR* mutations showed a significant longer PFS after Gefitinib treatment (15). In another study, Zhao *et al* demonstrated that the abundance of *EGFR* mutations could be a possible predictor to select patients with acquired resistance to primary TKIs that would benefit from EGFR-TKIs re-administration (16). Since the afore-mentioned *EGFR* mutations are critical for deciding the treatment strategies in patients with NSCLC, a reliable method to identify and measure the *EGFR* mutant abundance is urgently needed.

In the past decade, direct DNA sequencing was the most frequently used method for *EGFR* mutation detection. Despite its accessibility, the sensitivity is relatively low. The detection limit of direct DNA sequencing is approximately 20%, which may lead to a high rate of false negative result (17). More importantly, performing direct DNA sequencing requires a long processing time and could delay clinical-decision making. Currently, numerous detection methods have been investigating for the detection of *EGFR* mutations with a higher sensitivity (18,19). Amplification refractory mutation system (ARMS) is a detection method based on allele-specific polymerase chain reaction (PCR). The detection limit is reported to be around 1% which is far more sensitive than direct DNA sequencing. Droplet digital PCR (ddPCR) is another emerging method to detect *EGFR* mutations. Based on the compartmentalization and amplification of single DNA molecules, ddPCR is highly sensitive. Thus, it is now generally accepted as the most sensitive method for the detection and quantification of mutations (20). However, this method requires specialized equipment and it is more expensive in terms of cost and labor. Here, we introduce a modified ARMS-based assay, namely ARMS-Plus, for the analysis of *EGFR* mutations based on real time PCR platform. In the present study, ARMS-Plus and ddPCR methods were used to analyze FFPE-derived DNA samples, with the aim of comparing the performances of the two methods and exploring the feasibility of using ARMS-Plus in the measuring of *EGFR* mutant abundance.

Materials and methods

Sample collection and processing. FFPE tissue samples obtained from patients between 2013 and 2015 were collected

from the Guangdong Provincial Hospital of Traditional Chinese Medicine. Written informed consent was obtained from all of the patients. The present study protocol was approved by the Institutional Review Board of the Guangdong Provincial Hospital of Traditional Chinese Medicine. The FFPE tissue samples were micro-dissected by a pathologist and assessed by hematoxylin and eosin staining. Genomic DNA was extracted using the QIAamp® DNA FFPE Tissue kit (Qiagen, Shanghai, China). Collected FFPE-derived DNA samples were then analyzed by the following assays.

ARMS-plus. The isolated DNA samples were processed by Human *EGFR* Gene Mutation Quantitative Detection kit (Fluorescence qPCR; GenoSaber Biotech Co., Ltd., Shanghai, China) according to manufacturer's instructions. This is a quantitative PCR kit that can detect 4 different *EGFR* mutations with an external control in exon 4 to monitor samples qualities (Table I). In brief, 5 μ l samples were added to the pre-mixed 45 μ l reaction mixture came with the kit and the PCR was conducted with Applied Biosystems® 7500 Real-Time PCR Systems (Thermo Fisher Scientific, Inc., Waltham, MA, USA). PCR amplification conditions were as follow: hot start at 95°C for 4 min, and 50 cycles of 95°C for 10 sec, 61°C for 30 sec with fluorescence reading (FAM). Primer and probe sequences were listed in Table II. *19Del* mutation was detected by two separate reactions as two different kinds of base pair alteration were found. We also found that the 2361-site single nucleotide polymorphism (SNP) may affect PCR specificity, hence the *T790M* test was divided into two reactions to raise detection rate. The mutant abundance was defined as the percentage of mutant copies present in the whole DNA sample. To calculate the copy number, serially diluted plasmids were provided in the kit as standard samples for generating the standardization curve. Theoretically, the calculation equation of mutant abundance is shown as follow:

$$\text{Mutant abundance} = \frac{\text{Observed mutant copy number}}{\text{Observed wild type copy number}}$$

ddPCR. ddPCR was performed as previously described (21). In brief, the mixture of probes, primers, template DNA and 2X Droplet PCR Supermix (Bio-Rad Laboratories, Hercules, CA, USA) was applied to the droplet generator. The oil-in-water mixture generated was then transferred to a 96-well PCR plate, heat-sealed and placed in a C1000 Touch thermal cycler (Bio-Rad Laboratories) for PCR amplification. The following thermo-cycling conditions were used: Hot start at 95°C for 10 min, 40 cycles of 94°C for 30 sec, 62°C for 1 min, and 98°C for 10 min. The PCR product was read on a QX-200 droplet reader (Bio-Rad Laboratories) and the data were analyzed with QuantaLife software. The QuantaLife software calculates the copy number of both mutant and wild-type DNA based on the Poisson statistic.

ARMS-PCR. The isolated DNA samples were re-tested with ADx EGFR Mutations Detection kit (Amoy Diagnostics, Xiamen, China), which has received China Food and Drug Administration's (CFDA) approval for clinical usage in mainland China. The kit covered the 29 *EGFR* mutation hotspots from exon 18 to 21. The assay was carried out according to

Table I. Mutations or gene fragments detected by ARMS-Plus.

Site	Mutation	Exon	Base pair altered	Cosmic ID
EGFR external control	/	4	/	/
Del(1)	<i>E746_A750del(1)</i>	19	2235_2249del15	6223
Del(2)	<i>E746_A750del(2)</i>	19	2236_2250del15	6225
L858R	<i>L858R</i>	21	2573T>G	6224
T790M(1)	<i>T790M</i>	20	2369C>T	6240
T790M(2)	<i>T790M</i>	20	2361G>A/2369C>T	1451600/6240

The mutant abundance of *19Del* mutation is the sum of Del(1) and Del(2), while the one with a larger value between T790M(1) and T790M(2) was chosen as the *T790M* mutant abundance. COSMIC, catalogue of somatic mutations in cancer; *EGFR*, epidermal growth factor receptor; *19Del*, exon 19 deletion; ARMS, amplification refractory mutation system.

Table II. Sequence of primers and probes utilized for ARMS-Plus.

Site	Primer	Probe	Blocker
EGFR external control	Forward: 5'-TGGAGAGCAT CCAGT-3' Reverse: 5'-TCTGGAAGTC CATCGACAT-3'	5'FAM-ACATAGTCAG CAGTGACTT-3'MGB	/
Del(1)	Forward: 5'-CCGTCGCTAT CAAA-3' Reverse: 5'-ATGGACCCCC ACAC-3'	5'FAM-AAGCCAACAA GGAAAT-3'MGB	/
Del(2)	Forward: 5'-GTCGCTATCA AGA-3' Reverse: 5'-GTCGCTATCA AGA-3'	5'FAM-AAGCCAACAA GGAAAT-3'MGB	/
L858R	Forward: 5'-AGATTTTGGG CG-3' Reverse: 5'-TTTGCCTCCT TCTGC-3'	5'FAM-AACTGCTGGG TGC GGA-3'MGB	5'-TTTTTGGGCGGGCCA AAC-3' phosphorthioated
T790M(1)	Forward: 5'-CCGTGCAGCA CATCAT-3' Reverse: 5'-TGTCTTTGTG TTCCCG-3'	5'FAM-CTCATGCCCT TCGGC-3'MGB	5'-GCTCATCACGCAGCTCA-3' phosphorthioated
T790M(2)	Forward: 5'-CCGTGCAACA CATCAT-3' Reverse: 5'-TGTCTTTGTG TTCCCG-3'	5'FAM-CTCATGCCCT TCGGC-3'MGB	5'-CAACTCATCACGCAGCT-3' phosphorthioated

EGFR, epidermal growth factor receptor; ARMS, amplification refractory mutation system.

the manufacturer's protocol with the MX3000P (Stratagene; Agilent Technologies, Inc., Santa Clara, CA, USA) Real-Time PCR system.

Statistical analysis. The concordance rate of ARMS-Plus and ddPCR in identifying *EGFR* mutation status was analyzed by Kappa test. Samples were examined to determine whether a statistical difference existed regarding variations in *EGFR*

mutations between ARMS-Plus and ddPCR by the Wilcoxon test. $P < 0.05$ was considered to indicate statistical significance. The correlation between ARMS-Plus and ddPCR results on the *EGFR* mutant abundance was examined by Linear Regression analysis. The statistical analysis and graphic generation were carried out by using SAS9.2 (SAS Institute, Inc., Cary, NC, USA) and GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).




Figure 1. Detection of *EGFR* mutations by ARMS-Plus and ddPCR in spiked cell mixtures. Mutant cell lines were spiked into a *EGFR* wild-type cell line at a ratio of 1 and 5%. The mutant abundance was then detected. *EGFR* (A) *19Del*, (B) *L858R*, and (C) *T790M* mutations were stably detected by ARMS-Plus and ddPCR assays. Data are presented as the mean \pm standard error of the mean. *EGFR*, epidermal growth factor receptor; ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction; *19Del*, exon 19 deletion.

Results

Evaluation of the detection efficiency of ARMS-Plus. Mutant cell lines H1650 (*19Del*) and H1975 (*L858R* and *T790M*) were spiked into *EGFR* wild-type cell line A549 at a ratio of 1 and 5% (2×10^3 and 1×10^4 cells of each H1650 and H1975 was spiked into 2×10^5 cells of A549, respectively). QIAamp DNA FFPE Tissue Kit (Qiagen) was used to extract DNA from the cell mixtures. The final allelic frequencies were analyzed by both ARMS-Plus and ddPCR (3 repeats for each cell mixture). Results demonstrated that all mutations were stably detected by ARMS-Plus (Fig. 1). Generally, the mutant abundance detected by ddPCR was higher than that by ARMS-Plus.

Patients' enrollment. FFPE tumor samples from 77 lung adenocarcinoma patients were collected in this study (Table III). Of these patients, 45% (35/77) were female, median age was 62 years (range from 37-91 years), and 52% were never-smokers. Nearly half of the patients (45%, 35/77) were diagnosed with advanced stage disease (stage III-IV). Only 4 patients were treated with EGFR-TKI before sample collection.

Determination of *EGFR* mutation status. ARMS-Plus was performed to analyze the *EGFR* mutation status. The results were then re-tested by ddPCR and ARMS-PCR (Table IV).

Among the 77 paired samples evaluated by ddPCR, 35 (45.5%) samples were mutation positive and the other 42 samples were negative. For the ARMS-Plus results, only one sample showed a discordant result compared to that of ddPCR. A case of weak positive *L858R* result with an abundance of 0.5% detected by ARMS-Plus was recognized as negative by ddPCR (Table V). Together, the overall concordance rate of *EGFR* mutation testing between ARMS-Plus and ddPCR was 98.7% (76/77). The results of *EGFR* mutation status identified by the two methods were highly consistent (Kappa=0.9739, 95% CI: 0.923-1).

To evaluate the utility of ARMS-Plus for identifying *EGFR* mutations, we assessed the sensitivity and specificity of the assay compared to ddPCR (Table VI). For *19Del* and

T790M mutations, ARMS-Plus results were 100% matched with that of ddPCR. Only one case of *L858R* mutation was detected in ARMS-Plus but not ddPCR. The overall sensitivity and specificity for detecting *EGFR* mutations were 100 and 98% respectively, demonstrating the promise of ARMS-Plus in identifying *EGFR* mutations.

The ARMS-PCR results were also similar to that of ARMS-Plus and ddPCR. Only one case of positive *19Del* result confirmed by both ARMS-Plus and ddPCR was classified as negative by ARMS-PCR and one case of negative *19Del* result detected by both ARMS-Plus and ddPCR was shown positive for ARMS-PCR. Collectively, these data indicate that both ARMS-PCR, ddPCR and ARMS-Plus results were consistent in identifying *EGFR* mutations in FFPE-derived DNA samples.

Quantitative analysis of *EGFR* mutations. 23 out of 77 samples were identified to be *19Del* mutant by both ARMS-Plus and ddPCR. According to the results, significant difference was observed (Wilcoxon rank sum test, $P=0.0002$, Fig. 2A) between the abundance of *19Del* mutation detected by ARMS-Plus (median=25.26%) and ddPCR (median=43.76%). The observed *19Del* mutant abundance detected by ARMS-Plus was not consistent with the expected abundance based on ddPCR (Linear regression analysis, $R^2=0.1012$, Fig. 2B).

For *L858R* mutation, 12 out of 77 samples were identified by both ARMS-Plus and ddPCR. No significant difference was observed (Wilcoxon rank sum test, $P=0.7334$, Fig. 3A) between the abundance of *L858R* mutation detected by ARMS-Plus (median=31.18%) and ddPCR (median=26.27%). The observed *L858R* mutant abundance detected by ARMS-Plus was highly consistent with the expected abundance based on ddPCR (Linear regression analysis, $R^2=0.8081$, Fig. 3B).

The data of *T790M* mutant abundance were not analyzed as only 2 samples were identified with *T790M* mutation (both patients were EGFR-TKI treatment-naïve). However, the observed mutant abundance detected by ARMS-Plus is generally consistent with that of ddPCR (Case 1: 29.21% and 43.17%; Case 2: 11.18 and 16.42%, for ARMS-Plus and ddPCR, respectively).

Table III. Patient characteristics.

Variable	n (%)	EGFR mutation status detected by ddPCR	
		Mutant	Wild-type
Sex			
Female	35 (45)	24	11
Male	42 (55)	11	31
Age			
≥60 years	46 (60)	15	31
<60 years	31 (40)	20	11
Smoking history			
Ever-smoker	33 (43)	9	24
Never-smoker	40 (52)	26	14
Uncertain	4 (5)	0	4
Disease stage			
I	7 (9)	5	2
II	26 (34)	12	14
III	10 (13)	5	5
IV	25 (32)	12	13
Uncertain	9 (12)	1	8
EGFR mutation type			
<i>19Del</i>	21 (27)	21	0
<i>L858R</i>	12 (16)	12	0
<i>19Del+T790M</i>	2 (3)	2	0
Wild-type	42 (54)	0	42
Histopathology type			
Adenocarcinoma	77 (100)	35	42
Total n	77	35	42

EGFR, epidermal growth factor receptor; ddPCR, droplet digital polymerase chain reaction; *19Del*, exon 19 deletion.

Table IV. EGFR mutation status detected by ARMS-PCR, ddPCR and ARMS-Plus.

Mutation	ARMS-PCR	ddPCR	ARMS-Plus
Wild type	43	42	41
<i>19Del</i>	20	21	21
<i>L858R</i>	11	12	13
<i>19Del+L858R</i>	1	0	0
<i>19Del+T790M</i>	2	2	2
Total n	77	77	77

EGFR, epidermal growth factor receptor; ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction; *19Del*, exon 19 deletion.

Table V. Comparison of EGFR mutation status detected by ARMS-Plus and ddPCR.

Variable	ARMS-Plus results		
	EGFR Mutant (n)	Wild-type (n)	Total
ddPCR results			
EGFR Mutant (n)	35	0	35
Wild-type (n)	1	41	42
Total	36	41	77

EGFR, epidermal growth factor receptor; ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction.

Discussion

Since the approval of EGFR-TKIs in the last decade, a massive amount of researches have been investigating the clinical significance of EGFR mutations in predicting the sensitivity

of TKIs treatment (22,23). It is now apparent that EGFR mutations are associated with the efficacy of TKIs therapy. All NSCLC patients are suggested to perform EGFR mutation test after diagnosis to save cost and avoid unnecessary adverse effects due to wrong regimen decision (24). Recently, clinical

Table VI. Performance of ARMS-Plus compared with ddPCR.

Mutation	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Total n number
19Del	100	100	100	100	23
L858R	100	98	92	100	13
T790M	100	100	100	100	2
Total	100	98	97	100	36

19Del, exon 19 deletion; PPV, positive predictive value; NPV, negative predictive value; ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction.




Figure 2. Quantitative analysis of *19Del* mutation in paired samples. Comparison of AMRS-Plus and ddPCR results, evaluating *19Del* mutant abundance by (A) Wilcoxon rank sum test and (B) linear regression analysis. *19Del*, exon 19 deletion; ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction.




Figure 3. Quantitative analysis of *L858R* mutation in paired samples. Comparison of AMRS-Plus and ddPCR results, evaluating *L858R* mutant abundance by (A) Wilcoxon rank sum test and (B) linear regression analysis. ARMS, amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction.

study revealed that Osimertinib, a third-generation EGFR-TKI that can overcome T790M-resistance, showed a superior efficacy as first-line treatment to *EGFR*-mutated advanced NSCLC compared to first-generation EGFR-TKIs (25). Hence, a sensitive assay that can identify patients with 'de novo' T790M mutation could be valuable for selecting patients who are favorable to first-line Osimertinib treatment.

As NSCLC are often detected at advanced stages, small diagnostic biopsy specimens are the primary source for mutation detection. The DNA amount in these specimens is usually limited due to prior morphologic and immunophenotypic analysis. Thus, a highly sensitive assay is required for the detection of *EGFR* mutations. ddPCR is now generally accepted as the most sensitive method for evaluating mutations with low mutation rate. It utilizes a water-oil emulsion droplet system to separate DNA samples into thousands of nanoliter-sized droplets. The partitioning enables the measurement of thousands of independent amplification events within a single sample and extensively raises the sensitivity of the assay. In 2014, Zhang *et al* reported the superiority of ddPCR in detecting *EGFR* mutations. Results illustrated that ddPCR was able to detect and quantify *EGFR* mutations for as low as 0.12-2.73% (26). Despite the high sensitivity of ddPCR, the high cost and the requirement of unique equipment have greatly hampered its clinical application.

In the present study, we interpreted the ability of ARMS-Plus in identifying and quantifying *EGFR* mutations, with ddPCR as a standard. ARMS-Plus is an ARMS-based assay optimized for the quantification of 4 different *EGFR* mutations, including *19Del* at two different sites, *L858R*, and *T790M* mutations. Although only limited mutation sites are analyzed by ARMS-Plus, they represent the majority of mutations which have a well-established clinical significance in guiding EGFR-TKIs treatment selection. Moreover, the primers and probes of ARMS-Plus are optimized for *EGFR* mutation detection and the amplicon of each quantitative PCR is shortened to 50-80 bp. These features enable the precise analysis of highly fragmented DNA molecules extracted from FFPE tumor samples. To specifically quantify *EGFR* mutations, a kind of 3'-end-phosphorylated blocking primer was employed into the ARMS-Plus PCR reaction pools. By complementing the wild type DNA at the mutated sites, these primers block the non-specific elongations and raise the accuracy in quantification. In addition, ARMS-Plus can be conveniently performed with a real-time PCR system. These features of ARMS-Plus allow a rapid, reliable and cost-effective molecular analysis in clinical practice.

Cell experiment was performed to evaluate the detection efficiency of ARMS-Plus. *EGFR* mutations from well-studied cell lines (H1650 and H1975) were stably detected by both ARMS-Plus and ddPCR assays. Generally, the mutant abundance detected by ddPCR were higher than that by ARMS-Plus. This could be due to the possible non-specific amplification of wild-type template in ddPCR.

To explore the sensitivity of ARMS-Plus, a total of 77 FFPE tumor samples were analyzed for *EGFR* mutation statuses by both ARMS-PCR, ddPCR and ARMS-Plus. Micro-dissection was performed by a pathologist before the tests to remove normal tissues presented in the FFPE samples which could affect the quantification of mutations. All mutations found by ddPCR (35/77) were consistent with the results

of ARMS-Plus. Only one case of weak positive *L858R* mutation with an abundance of 0.5% was identified by ARMS-Plus, but not by ddPCR and ARMS-PCR. The overall concordance rate of *EGFR* mutation testing was 98.7% (Kappa=0.9739). These results demonstrated that ARMS-Plus is a promising assay with high sensitivity in detecting *EGFR* mutations.

In the quantification of *EGFR* mutations, the results varied with different types of mutation. For *L858R* mutation, there was no significant difference ($P=0.7334$) between the abundance detected by ARMS-Plus and ddPCR and a clear positive correlation was observed ($R^2=0.8081$). However, a significant difference was found ($P=0.0002$) between the abundance of *19Del* mutation detected by ARMS-Plus and ddPCR. The *19Del* mutant abundance detected by ARMS-Plus was not consistent with the expected abundance based on ddPCR ($R^2=0.1012$). The duplex probes used in ddPCR for detecting *19Del* mutation cover a larger region than that in ARMS-Plus (ddPCR: K749-S752 and A755-D761 region, ARMS-Plus: E746_A750 region) (21). This could probably explain the difference in *19Del* mutant abundance detected by the two methods, where the results of ddPCR were significantly higher than that of ARMS-Plus (median=43.76% vs. 25.26%). Further research with a larger sample size is required to clarify the ability of ARMS-Plus in evaluating *19Del* mutant abundance. For *T790M* mutation, because only 2 samples were identified, no analysis is performed to evaluate its correlation between ARMS-Plus and ddPCR.

There were a few limitations in this work. First, FFPE samples can only represent a unique tumor cell clones and cannot reflect the genetic heterogeneity of the whole tumor. The high sensitivity molecular screening for detection of *EGFR* mutations is at risk of over-qualification for EGFR-TKIs therapy. Therefore, combining liquid biopsy is a better option for decision making. Indeed, ddPCR has been proved to be sensitive enough to detect *EGFR* mutations in plasma samples (27). Further study to investigate the performance of ARMS-Plus in liquid biopsy is required. Second, due to the small sample size of this study, the performance of ARMS-Plus in quantifying *T790M* mutation cannot be assessed. Third, although micro-dissection was performed to ensure a >80% tumor content in each sample, the variation in tumor content could cause inaccurate quantification.

In conclusion, ARMS-Plus provides a reliable and cost-effective quantitative measuring tool with a similar sensitivity and specificity to ddPCR and could be applicable for evaluating *EGFR* mutations and guiding regimen selection in lung adenocarcinoma patients.

Acknowledgements

The authors Dr ZW Guo and Dr GH Yang are employees of GenoSaber Biotech Co., Ltd. (Shanghai, China). This company provided the Human *EGFR* Gene Mutation Quantitative Detection kit (Fluorescence qPCR) used in the present study and also provided technical support.

References

1. National Comprehensive Cancer Network (NCCN): Non-small cell lung cancer, Version 8.2017. NCCN Clinical Practice Guidelines in Oncology. NCCN, Fort Washington, PA, 2017.

2. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Grüning W, Bauer TT and Mairinger T: The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): Routine screening data for central Europe from a cohort study. *BMJ Open* 3: pii: e002560, 2013.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, *et al*: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. *Science* 304: 1497-1500, 2004.
4. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, *et al*: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 13: 239-246, 2012.
5. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, *et al*: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutation. *J Clin Oncol* 31: 3327-3334, 2013.
6. Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS J* 277: 301-308, 2010.
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, *et al*: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. *J Clin Oncol* 21: 2237-2246, 2003.
8. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, *et al*: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. *JAMA* 290: 2149-2158, 2003.
9. Usuda K, Sagawa M, Motono N, Ueno M, Tanaka M, Machida Y, Matoba M, Taniguchi M, Tonami H, Ueda Y and Sakuma T: Relationships between EGFR mutation status of lung cancer and preoperative factors-are they predictive? *Asian Pac J Cancer Prev* 15: 657-662, 2014.
10. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. *Cancer Res* 64: 8919-8923, 2004.
11. Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, *et al*: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. *Br J Cancer* 95: 1483-1489, 2006.
12. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y and Nukiwa T: Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. *J Clin Oncol* 24: 3340-3346, 2006.
13. Shih JY, Gow CH and Yang PC: EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. *N Engl J Med* 353: 207-208, 2005.
14. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. *J Clin Oncol* 30: 433-440, 2012.
15. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, *et al*: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. *J Clin Oncol* 29: 3316-3321, 2011.
16. Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY and Long H: Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance. *Med Oncol* 31: 810, 2014.
17. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M and Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. *J Mol Diagn* 7: 413-421, 2005.
18. Cushman-Vokoun AM, Crowley AM, Rapp SA and Greiner TC: Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. *Am J Clin Pathol* 140: 7-19, 2013.
19. Shaozhang Z, Ming Z, Haiyan P, Aiping Z, Qitao Y and Xiangqun S: Comparison of ARMS and direct sequencing for detection of EGFR mutation and prediction of EGFR-TKI efficacy between surgery and biopsy tumor tissues in NSCLC patients. *Med Oncol* 31: 926, 2014.
20. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M and Speake G: A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. *J Exp Clin Cancer Res* 29: 132, 2010.
21. Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M and Zheng G: Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. *Oncotargets Ther* 8: 1533-1541, 2015.
22. Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, *et al*: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated Erlotinib and chemotherapy. *Clin Cancer Res* 21: 3196-3203, 2015.
23. Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Chen JJ and Chang GC: Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. *J Thorac Oncol* 10: 603-610, 2015.
24. Lilienbaum RA and Horn LA: Management of EGFR mutation-positive non-small cell lung cancer. *J Natl Compr Canc Netw* 14 (5 Suppl): S672-S674, 2016.
25. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenzov Y, *et al*: Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. *J Clin Oncol*: Aug 25, 2017 (Epub ahead of print).
26. Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, Li XB, Zhang Z, Wang WJ, Li LQ and Cai CL: Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. *Exp Ther Med* 9: 1383-1388, 2015.
27. Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, McCormack R, Gu Y and Liu X: Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. *J Mol Diagn* 17: 265-272, 2015.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.